v3.22.2.2
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 506,098 $ 1,844,732
Short-term investments 0 134,603
Accounts receivable 183,383 216,183
Prepaid expenses 97,515 981,895
Contract asset 178,048 132,572
Other current assets 248,457 837,358
Total current assets 1,213,501 4,147,343
Non-current assets:    
Operating lease right-of-use assets 914,226 964,331
Restricted cash 0 5,000,000
Goodwill 9,267,007 9,267,007
Intangible assets, net 1,239,853 1,580,980
Property and equipment, net 106,415 201,901
Total non-current assets 11,527,501 17,014,219
Assets of discontinued operation 8,123 8,123
Total assets 12,749,125 21,169,685
Current liabilities:    
Accounts payable and accrued expenses 14,442,069 5,715,956
Current portion of operating lease liabilities 323,631 254,998
Deferred revenue 386,929 373,468
Stock issuances due 682,078 325,828
Notes payable 6,396,486 4,575,000
Total current liabilities 22,231,193 11,245,250
Operating lease liabilities, net of current portion 686,140 806,140
Long-term debt 0 10,625,000
Total long-term liabilities 686,140 11,431,140
Liabilities of discontinued operation 63 63
Total liabilities 22,917,396 22,676,453
Stockholders’ equity (deficit):    
Preferred stock, $.005 par value; 1,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021 0 0
Common stock, $.005 par value; 150,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 50,744,653 shares issued and outstanding as of September 30, 2022 and 35,484,106 shares issued and outstanding as of December 31, 2021 253,724 177,421
Additional paid-in capital 133,526,843 127,743,333
Accumulated other comprehensive income (loss) 53,695 (6,651)
Accumulated deficit (144,075,557) (129,482,141)
Total Statera Biopharma, Inc. stockholders’ deficit (10,241,295) (1,568,038)
Noncontrolling interest in stockholders’ equity 73,024 61,270
Total stockholders’ deficit (10,168,271) (1,506,768)
Total liabilities and stockholders’ deficit $ 12,749,125 $ 21,169,685